Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 18, 2022

BUY
$7.42 - $11.05 $63,982 - $95,284
8,623 New
8,623 $95,000
Q2 2021

Jul 19, 2021

SELL
$14.52 - $22.46 $21,780 - $33,690
-1,500 Closed
0 $0
Q1 2021

Apr 26, 2021

BUY
$16.57 - $21.08 $24,855 - $31,619
1,500 New
1,500 $30,000
Q2 2020

Jul 22, 2020

SELL
$20.64 - $30.69 $20,640 - $30,690
-1,000 Closed
0 $0
Q1 2020

May 07, 2020

BUY
$17.84 - $31.21 $17,840 - $31,210
1,000 New
1,000 $23,000
Q4 2019

Feb 06, 2020

SELL
$16.12 - $25.89 $6,270 - $10,071
-389 Closed
0 $0
Q3 2019

Oct 28, 2019

SELL
$16.51 - $23.78 $284,913 - $410,371
-17,257 Reduced 97.8%
389 $7,000
Q2 2019

Aug 09, 2019

BUY
$15.6 - $25.15 $142,677 - $230,021
9,146 Added 107.6%
17,646 $288,000
Q1 2019

May 10, 2019

BUY
$22.57 - $28.15 $191,845 - $239,275
8,500 New
8,500 $192,000

Others Institutions Holding TBPH

About Theravance Biopharma, Inc.


  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $640M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.